Treatments of non-alcoholic steatohepatitis (NASH)

Patent metadata

Field	Value
Publication number	US-11052102-B2
Application number	US-201716307643-A
Country	US
Kind code	B2
Filing date	Jun 28, 2017
Priority date	Jun 28, 2016
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.

First claim

The invention claimed is:

1. A method for the treatment of non-alcoholic steatohepatitis (NASH), wherein said method comprises administering, to a subject in need of such treatment, an inhibitor of thrombocyte aggregation or activation, wherein said inhibitor is an anti Gp1b antibody that specifically and selectively binds to a Gp1b protein and inhibits its function.

2. The method according to claim 1 , wherein the treatment is an alleviation or a reduced progression of NASH.

3. The method according to claim 1 , wherein the treatment is a reduced, stalled, or reversed progression of NASH into liver cirrhosis.

4. The method according to claim 1 , wherein the treatment is a prevention of HCC in a NASH-patient at risk to develop cirrhosis and/or HCC.

5. The method according to claim 1 , wherein the treatment is performed in a patient at risk of developing NASH, wherein the patient is a diabetic patient, an obese patient, or a patient suffering from metabolic syndrome or from another metabolic disorder.

6. The method according to claim 1 , wherein the subject to be treated does not have a condition selected from the group consisting of alcoholic liver injury, drug-induced liver injury, chronic active hepatitis, hepatic steatosis and hepatocyte apoptosis.

7. The method according to claim 1 , wherein the treatment is a reduced, stalled, or reversed progression of NASH into hepatocellular carcinoma (HCC).

8. The method, according to claim 6 , wherein the patient suffers from an inflamed fatty liver.

Assignees

• Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Inventors

• Heikenwälder Mathias
• Zender Lars
• Weber Achim

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C12N2310/11

  Antisense · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K31/7105 Primary

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title